ALBANY, New York, May 10, 2017 /PRNewswire/ --
Several players operate in the global Cancer Biomarkers Market, catering to niche segment. The global biomarkers market offers a favorable environment for competitors as there are several unique customer segments within the industry, exhibiting demand for distinct product type. However, as market players target multiple pathways, in the near future the market could witness increased competition. Abbott Laboratories, Merck & Co., Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., and bioMérieux SA are among the leading market players, finds Transparency Market Research (TMR) in a new study.
Considering the dynamic business environment, a majority of the market players are focusing on achieving greater market share via product differentiation. The research and development spending is thus significantly high in the market. Besides this, several companies are aiming at expanding their footprint through acquisitions and disinvestments. As the companies continue spending on product development and technological advancements, consequently the cancer biomarkers market will witness greater opportunities for growth.
According to TMR, the global cancer biomarkers market, which stood at US$10.25 bn in 2016, is expected to reach US$27.63 bn by the end of 2027. If these figures hold true, the global cancer biomarkers market will exhibit a CAGR of 11.8% between 2017 and 2025. By disease indication, the demand for cancer biomarkers was the highest for the treatment of lung cancer, which is likely to hold nearly 25.8% of the market by the end of 2017. Regionally, North America held the dominant share of 42.5% of the global market in 2016.
Rising Funding for Cancer Research to Boost Growth Opportunities
The market is majorly gaining from the rising discretionary funding for cancer research. Governments across most developed countries are engaged in raising funds for cancer research to aid in diagnosis and research. They are also funding clinical trials for breakthroughs in cancer treatment. As their initiatives gain pace, the cancer biomarkers market will witness greater growth opportunities. Also steps taken by the government to spread cancer awareness will help the market gain momentum. In lines with the same, the demand for cancer biomarkers will therefore rise in response to the rising incidence of cancer worldwide.
To gain a stronger foothold, the leading market players are forging strategic collaborations. They are also keen on acquiring established regional players to expand their geographic footprint. Such strategies adopted by companies will have a positive influence on the market. Besides these, growing acceptance of patients towards innovative technologies and tests and novel product launches will enable the market exhibit strong growth during the forecast period.
Inquire for a Sample Copy of Report @ http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=479
Lack of Awareness to Act as Major Restraint to Growth
On the downside, the unwillingness of healthy population to participate in clinical research is acting against the market's growth prospects. While overall, the incidence of cancer cases is surging around the world, but not many of them have access to proper treatment. This is partly due to the lack of participation in clinical trials and unavailability of patient surveillance systems. Given the scenario, low awareness and ambiguity regarding blood tests such as tumor biomarkers are inhibiting the cancer biomarker market's trajectory. Also the high attrition rate in product development cycle is restricting the market's growth to an extent.
Nevertheless, with the advent of minimal-invasive diagnostic tests for cancer diagnosis will support the market's growth in the near future. Minimally invasive diagnosis will provide simple and comparatively less expensive method of detecting cancer. These innovations will bring in fresh opportunities for the market players to capitalize on. Also the market will witness considerable growth opportunities as governments across emerging nations boost their healthcare spending and take steps to deliver healthcare services at par with the international standards.
This review is based on a TMR report, titled "Cancer Biomarkers Market (Test Type - PSA Tests, CTC Tests, AFP Tests, CA Tests, HER2 Tests, BRCA Tests, ALK Tests, CEA Tests, EGFR Mutation Tests, and KRAS Mutation Tests; Disease Indication - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Blood Cancer, Prostate Cancer, Ovarian Cancer, Stomach Cancer, and Liver Cancer) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025."
The report segments the global Cancer Biomarkers Market as:
Global Cancer Biomarkers Market, by Test Type
- PSA Tests
- CTC Tests
- AFP Tests
- CA Tests
- HER2 Tests
- BRCA Tests
- ALK Tests
- CEA Tests
- EGFR Mutation Tests
- KRAS Mutation Tests
Global Cancer Biomarkers Market, by Disease Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Blood Cancer
- Prostate Cancer
- Ovarian Cancer
- Stomach Cancer
- Liver Cancer
Global Cancer Biomarkers Market, by Geography
- North America
- Rest of Europe
- Asia Pacific
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- GCC countries
- South Africa
- Rest of MEA
Browse Related Research Report:
Central Nervous System (CNS) Biomarkers Market
Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
SOURCE Transparency Market Research